Immuno Oncology

May 10, 2021

Study indicates that high mutational burden does not predict response to immunotherapy for different type of cancers

The high tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoints inhibitors (ICI), largely because of its potential to generate immunogenic neoantigens. Despite the recent […]
April 28, 2021

New transcriptional subtype of small cell lung cancer has increased sensitivity to immunotherapy

Although the new standard of treatment for the extensive disease involves the integration of platinum, etoposide and immunotherapy considering the statistical gain in survival, this benefit is limited in unselected populations, emphasizing […]
April 26, 2021

Neoadjuvant cemiplimab for the treatment of resectable hepatocellular carcinoma demonstrates pathological complete response rates

Neoadjuvant immunotherapy can induce pathological responses and immunological memory in different malignancies, being a potential therapy for hepatocellular carcinoma   A multi-cohort, phase II study (NCT03916627) of neoadjuvant cemiplimab (an anti-PD-1 antibody) for the treatment […]
April 23, 2021

Tislelizumab, a new anti-PD-1 antibody, is an alternative for second- and third-line treatment in advanced NSCLC

RATIONALE 303 trial, presented at AACR 2021, compared the efficacy and safety of monoclonal antibody versus docetaxel   The RATIONALE 303 trial (NCT03358875), which compared the efficacy and safety of tislelizumab versus docetaxel as second- or third-line therapy for […]
April 23, 2021

EVICTION is the first-in-human trial of γ9δ2 T-cell antitumor response in solid and hematological tumors with the ICT01 drug

Gamma9 Delta2 (γ9δ2) T cells function at the crossroads of innate and adaptive immunity, with important roles in immune responses against pathogens and carcinogenesis, making them an attractive […]
April 22, 2021

Sintilimab is superior to docetaxel as a second-line treatment for advanced/metastatic SCC of the lung

Patients with advanced lung squamous cell carcinoma (SCC) have very limited second-line treatment options after platinum doublet treatment failure   ORIENT-3 (NCT03150875), a phase III, randomized, open-label and multicenter trial was presented in […]
April 22, 2021

Combination copanlisib plus rituximab demonstrates broad efficacy and superiority versus placebo plus rituximab in patients with relapsed iLNH

Rituximab-based therapies are standard in the treatment of relapsed or refractory indolent non-Hodgkin lymphoma (iLNH). Copanlisib, an intravenous PI3K inhibitor, has demonstrated efficacy and safety as monotherapy […]
April 20, 2021

Combination of avelumab, trastuzumab and mFOLFOX6 demonstrates clinical activity in metastatic gastroesophageal adenocarcinoma with HER2 amplification

Trastuzumab is a monoclonal antibody directed to HER2, indicated in combination with chemotherapy in 20 to 30% metastatic esophageal or gastric adenocarcinomas that overexpress HER2. However, the […]
February 3, 2020

Newly discovered T-cell Receptor has an ample capacity to recognize and eliminate tumor cells

A group of scientists from different research groups discovered and isolated a subpopulation of CD8 + T lymphocytes (cytotoxic) that attack tumor cells – from different […]